GeneDx (NASDAQ:WGS) COO Bryan Dechairo Sells 3,413 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) COO Bryan Dechairo sold 3,413 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $99.53, for a total transaction of $339,695.89. Following the sale, the chief operating officer owned 5,961 shares in the company, valued at $593,298.33. This trade represents a 36.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

GeneDx Stock Down 3.8%

Shares of WGS stock opened at $95.23 on Wednesday. The firm has a market capitalization of $2.75 billion, a P/E ratio of 1,058.11 and a beta of 2.00. The firm’s fifty day moving average price is $131.03 and its two-hundred day moving average price is $125.13. The company has a current ratio of 2.71, a quick ratio of 2.59 and a debt-to-equity ratio of 0.18. GeneDx Holdings Corp. has a 1 year low of $55.17 and a 1 year high of $170.87.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, January 21st. Canaccord Genuity Group increased their target price on GeneDx from $160.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, December 22nd. BTIG Research upped their target price on GeneDx from $165.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Guggenheim reaffirmed a “buy” rating and set a $170.00 price target (up from $115.00) on shares of GeneDx in a report on Wednesday, October 29th. Finally, Wells Fargo & Company set a $155.00 price objective on shares of GeneDx and gave the company an “equal weight” rating in a research note on Monday, December 15th. Six investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, GeneDx has an average rating of “Moderate Buy” and an average price target of $138.13.

Institutional Investors Weigh In On GeneDx

A number of institutional investors have recently modified their holdings of WGS. William Blair Investment Management LLC boosted its position in shares of GeneDx by 37.2% during the 2nd quarter. William Blair Investment Management LLC now owns 1,631,402 shares of the company’s stock worth $150,595,000 after purchasing an additional 442,414 shares in the last quarter. Vanguard Group Inc. boosted its holdings in GeneDx by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 1,189,069 shares of the company’s stock worth $154,650,000 after acquiring an additional 18,647 shares in the last quarter. Franklin Resources Inc. grew its stake in GeneDx by 101.9% in the third quarter. Franklin Resources Inc. now owns 681,381 shares of the company’s stock valued at $73,412,000 after acquiring an additional 343,954 shares during the period. Westfield Capital Management Co. LP increased its holdings in shares of GeneDx by 164.8% during the second quarter. Westfield Capital Management Co. LP now owns 589,188 shares of the company’s stock valued at $54,388,000 after acquiring an additional 366,711 shares in the last quarter. Finally, Zweig DiMenna Associates LLC grew its holdings in shares of GeneDx by 28.2% during the second quarter. Zweig DiMenna Associates LLC now owns 586,100 shares of the company’s stock valued at $54,103,000 after buying an additional 129,000 shares during the last quarter. 61.72% of the stock is owned by institutional investors.

Key Headlines Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Analyst consensus remains favorable — the stock carries a “Moderate Buy” consensus and several firms have recently reaffirmed or raised price targets, which supports longer-term upside. Analyst Consensus
• Neutral Sentiment: Institutional ownership is sizable (~61.7%) with modest quarter-to-quarter adjustments by some funds; that large institutional base can dampen short-term volatility but also concentrates moves when sentiment shifts. Institutional & Insider Summary
• Neutral Sentiment: Reported short-interest data in the recent update is effectively zero/insignificant (likely a data anomaly), so short-covering dynamics are not a clear driver of today’s move. No clear short squeeze risk is indicated.
• Negative Sentiment: Multiple insider sales by senior executives: COO Bryan Dechairo sold 3,413 shares (~$339.7k) and CEO Katherine Stueland sold 1,653 shares (both late January transactions disclosed in SEC filings). Such clustered insider selling by C‑suite members can signal to the market a reduced near-term insider conviction. COO Form 4 CEO Form 4
• Negative Sentiment: CFO Kevin Feeley also sold shares (317 shares reported), adding to the pattern of insider sales and amplifying investor concern about executive liquidity events. CFO Sale
• Negative Sentiment: Technical picture is unfavorable: the share price sits well below the 50-day and 200-day moving averages cited in recent summaries, which can prompt momentum selling from traders using technical triggers. Price & Technicals

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.